Effects of CPAP on Visceral Fat Thickness

Chinese University of Hong Kong141 enrolled

Overview

We hypothesize that patients with untreated OSAS will have more visceral fat, fatty liver and increased carotid artery thickness whereas treatment with CPAP may reduce the mesenteric and liver fat, plasma lipids, carotid artery thickness.

This proposed randomized control trial (RCT) will compare the effects of therapeutic CPAP versus subtherapeutic CPAP in patients newly diagnosed with OSA with reference to visceral fat especially mesenteric fat thickness, liver fat, carotid artery intima media thickness (IMT), lateral pharyngeal wall (LPW) thickness, plasma lipids and adipokines over a treatment period of 3 months. The results of this study will advance our understanding of the relative role of OSA and obesity in the pathogenesis of metabolic syndrome (MetS) and whether CPAP therapy can improve these metabolic dysregulation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

141

Conditions

Obstructive Sleep Apnea

Interventions

CPAPDEVICE

All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * symptomatic patients with OSA of apnea hypopnea index (AHI) \>= 5/hr Exclusion Criteria: * Recent or past history of myocardial infarction/stroke/heart failure, unstable angina, underlying malignancy, * patients with clinical features of any active infection * those who require urgent CPAP treatment because of associated respiratory failure or to prevent job loss through excessive daytime sleepiness (eg professional drivers, those handling dangerous machinery) * moderate to severe valvular heart disease, cardiomyopathy, and previous diagnosis of OSA and/or previous use of CPAP therapy.

Locations (1)

Respiratory Division

Hong Kong, China

Outcomes

Primary Outcomes

Mesenteric Fat Thickness

Time frame: 3 months

Secondary Outcomes

Mean Changes in Adiponectin Over 3 Months

Mean changes in Adiponectin from baseline to 3 months.

Time frame: Baseline, 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.